New test aims to personalize prostate cancer care, reduce side effects

This study is looking at whether a genetic test called the Genomic Prostate Score (GPS) can work together with MRI scans to help doctors better select patients for a less-invasive prostate cancer treatment called focal therapy. Researchers will analyze past data and tissue samples from about 240 men who had surgery for low or intermediate-risk prostate cancer. The goal is to see if the GPS test can identify which cancers might be more aggressive than they appear on an MRI, helping future patients avoid unnecessary side effects from more extensive treatments.